


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:


**Listing of Claims:**

1. (original) A compound of the formula I:



wherein:

$A^1$  is a monocyclic or bicyclic heteroaromatic ring system selected from:



wherein:

Application No.: 10/759,749

Confirmation No.: 8348

Page 2 of 13

$R^1$  is, in each instance, independently, hydrogen,  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  alkenyl,  $C_1$ - $C_8$  acyl, aryloxy carbonyl, alkyloxy carbonyl, or trialkylsilyl;

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  are, in each instance, independently selected from hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  alkyl amino,  $C_3$ - $C_7$  cycloalkyl, aryl, heteroaryl, and heterocyclyl;

$R^8$  is independently, in each instance, selected from hydrogen, halogen, nitrile, nitro,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, alkylcarbonyl, alkoxy carbonyl,  $C_3$ - $C_7$  cycloalkyl, nitro,  $OR^8$ ,  $SR^8$ ,  $NR^8R^9$ ,  $N(O)R^8R^9$ ,  $P(O)(OR^8)(OR^9)$ ,  $(CR^8R^9)_nNR^{10}R^{11}$ ,  $COR^8$ ,  $(CR^8R^9)_nC(O)R^{10}$ ,  $CO_2R^8$ ,  $CONR^8R^9$ ,  $C(O)NR^8SO_2R^9$ ,  $NR^8SO_2R^9$ ,  $C(O)NR^8OR^9$ ,  $S(O)_nR^8$ ,  $SO_2NR^8R^9$ ,  $(CR^8R^9)_nP(O)(OR^{10})(OR^{11})$ ,  $(CR^8R^9)_n$ -aryl,  $(CR^8R^9)_n$ -heteroaryl,  $-T(CH_2)_mQR^8$ ,  $-C(O)T(CH_2)_mQR^8$ ,  $NR^8C(O)T(CH_2)_mQR^8$ , and  $-CR^8=CR^8C(O)R^{10}$ ;

$R^7$  is independently, in each instance, hydrogen,  $C_1$ - $C_{10}$  acyl, alkyloxy carbonyl, aryloxy carbonyl,  $C_1$ - $C_8$  alkyl, or  $C_2$ - $C_8$  alkenyl,

$R^{12}$  is independently, in each instance, hydrogen,  $C_1$ - $C_{10}$  acyl, arylalkyl, alkylamino, arylamino, or alkylamino;

$R^8$  and  $R^9$  may optionally form a carbocyclic group containing 3-7 members preferably 5-6 members, up to four of which are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups said groups in each instance independently selected from halogen, hydroxy, hydroxyalkyl, nitrile, lower alkyl, lower alkoxy, alkoxy carbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino,  $(CH_2)_nC(O)NR^{10}R^{11}$ , and  $O(CH_2)_nC(O)OR^{10}$ ;

T is, in each instance, independently, O, S,  $NR^9$ ,  $N(O)R^9$ , or  $CR^9R^{10}$ ;

Q is, in each instance, independently, O, S,  $NR^9$ ,  $N(O)R^9$ ,  $CO_2$ ,  $O(CH_2)_n$ -heteroaryl,  $O(CH_2)_nS(O)_mR^9$ , or  $(CH_2)$ -heteroaryl;

X and Y are in each instance independently selected from hydrogen, halogen, nitrile,  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  alkylcarbonyl,  $C_1$ - $C_8$  alkoxy carbonyl, nitro,  $OR^8$ ,  $SR^8$ ,  $NR^8R^9$ ,  $N(O)R^8R^9$ ,  $P(O)(OR^8)(OR^9)$ ,  $(CR^8R^9)_nNR^{10}R^{11}$ ,  $COR^8$ ,  $(CR^8R^9)_nC(O)R^{10}$ ,  $CO_2R^8$ ,  $CONR^8R^9$ ,  $C(O)NR^8SO_2R^9$ ,  $NR^8SO_2R^9$ ,  $C(O)NR^8OR^9$ ,  $S(O)_nR^8$ ,  $SO_2NR^8R^9$ ,  $(CR^8R^9)_nP(O)(OR^{10})(OR^{11})$ ,  $(CR^8R^9)_n$ -aryl,  $(CR^8R^9)_n$ -heteroaryl,  $-T(CH_2)_mQR^8$ ,  $-C(O)T(CH_2)_mQR^8$ ,  $NR^8C(O)T(CH_2)_mQR^8$ , and  $-CR^8=CR^8C(O)R^{10}$ ;

W is selected from hydrogen, halogen,  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_1$ - $C_8$  alkoxy,  $C_1$ - $C_8$  alkoxyalkyl,  $C_1$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  hydroxyalkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, nitrile, nitro,  $OR^8$ ,  $SR^8$ ,  $NR^8R^9$ ,  $N(O)R^8R^9$ ,  $P(O)(OR^8)(OR^9)$ ,  $(CR^8R^9)_nNR^{10}R^{11}$ ,  $COR^8$ ,  $(CR^8R^9)_nC(O)R^{10}$ ,  $CO_2R^8$ ,  $CONR^8R^9$ ,  $C(O)NR^8SO_2R^9$ ,  $NR^8SO_2R^9$ ,  $C(O)NR^8OR^9$ ,  $S(O)_nR^8$ ,  $SO_2NR^8R^9$ ,  $(CR^8R^9)_nP(O)(OR^{10})(OR^{11})$ ,  $(CR^8R^9)_n$ -aryl,  $(CR^8R^9)_n$ -heteroaryl,  $-T(CH_2)_mQR^8$ ,  $-C(O)T(CH_2)_mQR^8$ ,  $NR^8C(O)T(CH_2)_mQR^8$ , and  $-CR^8=CR^8C(O)R^{10}$ ;

Application No.: 10/759,749

Confirmation No.: 8348

Page 3 of 13

W and one of X or Y may optionally form an aromatic ring containing up to three heteroatoms and optionally substituted by up to 4 groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxy carbonyl, alkyl carbonyl, alkyl carbonylamino, and aminoalkyl, aminoalkyl carbonyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethylalkylaminoalkyl, amino, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl, nitrile,  $\text{NR}^8\text{SO}_2\text{R}^9$ ,  $\text{C(O)NR}^8\text{R}^9$ ,  $\text{NR}^8\text{C(O)R}^9$ ,  $\text{C(O)OR}^8$ ,  $\text{C(O)NR}^8\text{SO}_2\text{R}^9$ ,  $(\text{CH}_2)_n\text{S(O)}_n\text{R}^8$ ,  $(\text{CH}_2)_n$ -heteroaryl,  $\text{O}(\text{CH}_2)_n$ -heteroaryl,  $(\text{CH}_2)_n\text{C(O)NR}^8\text{R}^9$ ,  $\text{O}(\text{CH}_2)_n\text{C(O)OR}^8$ ,  $(\text{CH}_2)_n\text{SO}_2\text{NR}^8\text{R}^9$ , and  $\text{C(O)R}^8$ ;


Z is in each instance, independently, O or  $\text{NR}^6$ ;

m is an interger of from 1-6;

n is an interger of from 0-6; and

the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

2. (original) A compound of Claim 1, having the following structure:



Formula II

wherein:

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ , T, Q, W, X, Y, m and n are as defined as for Formula I.

3. (original) A compound of claim 1 wherein  $\text{R}^1$  and  $\text{R}^2$  are independently, in each instance, hydrogen.
4. (original) A compound according to claim 1 wherein  $\text{R}^4$  is alkyl.
5. (original) A compound according to claim 1 wherein  $\text{R}^6$  is halogen or  $\text{COR}^5$ .
6. (original) A compound according to claim 1 wherein W is  $\text{NR}^8\text{R}^9$ .
7. (original) A compound of claim 1 wherein Z is O.

Application No.: 10/759,749

Confirmation No.: 8348

Page 4 of 13

8. (original) A compound according to claim 1 wherein  $R^{12}$  is  $PhCH_2NH$ .
9. (original) A compound according to claim 1 wherein X and Y are hydrogen.
10. (original) A compound according to claim 1 wherein  $R^3$  is halogen, or  $C_1-C_8$  alkyl.
11. (original) A compound according to claim 1 selected from the group consisting of:  
4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile,  
N4-Cyclopentyl-5-nitro-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,  
4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbaldehyde,  
4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carboxylic acid ethyl ester,  
4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carboxylic acid methyl ester,  
[4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-methanol,  
1-[4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-ethanone,  
3-[4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-but-2-enoic acid ethyl ester,  
4-Amino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile,  
5-Nitro-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,  
4-Amino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbaldehyde,  
4-Amino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carboxylic acid ethyl ester,  
4-Amino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carboxylic acid methyl ester,  
[4-Amino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-methanol,  
1-[4-Amino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-ethanone,  
3-[4-Amino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-but-2-enoic acid ethyl ester,  
4-Cyclopentylamino-2-(5-pyrrolidin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile,  
N2-[5-(3-Amino-pyrrolidin-1-yl)-pyridin-2-yl]-N4-cyclopentyl-5-nitro-pyrimidine-2,4-diamine,  
4-Cyclopentylamino-2-(5-morpholin-4-yl-pyridin-2-ylamino)-pyrimidine-5-carbaldehyde,  
4-Cyclopentylamino-2-(3,4,5,6-tetrahydro-2H-[1,3]bipyridinyl-6'-ylamino)-pyrimidine-5-carboxylic acid ethyl ester,  
4-Cyclopentylamino-6-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carboxylic acid methyl ester,  
{2-[5-(Bis-methoxymethyl-amino)-pyridin-2-ylamino]-4-cyclopentylamino-pyrimidin-5-yl}-methanol,

Application No.: 10/759,749

Confirmation No.: 8348

Page 5 of 13

1-[4-Benzylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-ethanone,  
4-[4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-pent-3-en-2-one,  
4-Amino-2-(pyridin-2-ylamino)-pyrimidine-5-carbonitrile,  
5-Nitro-N2-pyridin-2-yl-pyrimidine-2,4-diamine,  
4-Amino-2-(pyridin-2-ylamino)-pyrimidine-5-carbaldehyde,  
4-Amino-2-(pyridin-2-ylamino)-pyrimidine-5-carboxylic acid ethyl ester,  
5-Bromo-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,  
[4-Amino-2-(5-morpholin-4-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-methanol,  
1-[4-Amino-2-(5-morpholin-4-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-ethanone,  
[6-(5-Acetyl-4-amino-pyrimidin-2-ylamino)-pyridin-3-yloxy]-acetic acid,  
4-Cyclopentylamino-2-(4-hydroxymethyl-5-pyrrolidin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile,  
N2-[5-(3-Amino-pyrrolidin-1-yl)-6-chloro-pyridin-2-yl]-N4-cyclopentyl-5-nitro-pyrimidine-2,4-diamine,  
2-(5-Bromo-pyridin-2-ylamino)-4-cyclopentylamino-pyrimidine-5-carbaldehyde,  
4-Cyclopentylamino-2-(1H-pyrrolo[3,2-b]pyridin-5-ylamino)-pyrimidine-5-carboxylic acid ethyl ester,  
4-Cyclopentylamino-2-(4,6-dichloro-5-piperazin-1-yl-pyridin-2-ylamino)-6-methyl-pyrimidine-5-carboxylic acid methyl ester,  
2-[2-{5-[Bis-(2-methoxy-ethyl)-amino]-pyridin-2-ylamino}-4-cyclopentylamino-pyrimidin-5-yl]-2-methyl-propan-1-ol,  
1-[4-Phenylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-ethanone,  
4-[4-(3-Hydroxy-cyclopentylamino)-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-pent-3-en-2-one,  
4-[5-Cyano-2-(pyridin-2-ylamino)-pyrimidin-4-ylamino]-cyclohexanecarboxylic acid,  
2-(4-Amino-5-nitro-pyrimidin-2-ylamino)-isonicotinic acid,  
4-Amino-6-methyl-2-(pyridin-2-ylamino)-pyrimidine-5-carbaldehyde,  
5-Iodo-N2-pyridin-2-yl-pyrimidine-2,4-diamine,  
N-[5-Bromo-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-4-yl]-acrylamide,  
N2-(5-Piperazin-1-yl-pyridin-2-yl)-5-prop-1-ynyl-pyrimidine-2,4-diamine,  
5-[2-(4-Fluoro-phenyl)-ethyl]-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,  
[6-(4-Amino-5-propenyl-pyrimidin-2-ylamino)-pyridin-3-yloxy]-acetic acid,  
5-Bromo-N4-cyclopentyl-N2-(5-pyrrolidin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,  
N2-[5-(3-Amino-pyrrolidin-1-yl)-6-chloro-pyridin-2-yl]-5-bromo-N4-cyclopentyl-pyrimidine-2,4-diamine,  
5-Bromo-N4-cyclopentyl-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,

Application No.: 10/759,749  
Confirmation No.: 8348  
Page 6 of 13

5-Bromo-N4-cyclopentyl-N2-(1H-pyrrolo[3,2-b]pyridin-5-yl)-pyrimidine-2,4-diamine,  
5-Bromo-N4-cyclopentyl-N2-(4,6-dichloro-5-piperazin-1-yl-pyridin-2-yl)-6-methyl-pyrimidine-2,4-diamine,  
N2-[5-[Bis-(2-methoxy-ethyl)-amino]-pyridin-2-yl]-5-bromo-N4-cyclopentyl-pyrimidine-2,4-diamine,  
5-Bromo-N4-phenyl-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,  
3-[5-Bromo-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-4-ylamino]-cyclopentanol,  
N4-Cyclopentyl-5-iodo-N2-(5-pyrrolidin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,  
N2-[5-(3-Amino-pyrrolidin-1-yl)-6-chloro-pyridin-2-yl]-N4-cyclopentyl-5-iodo-pyrimidine-2,4-diamine,  
N4-Cyclopentyl-5-iodo-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine,  
N4-Cyclopentyl-5-iodo-N2-(1H-pyrrolo[3,2-b]pyridin-5-yl)-pyrimidine-2,4-diamine,  
4-[6-(5-Bromo-4-cyclopentylamino-pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester,  
4-[6-(4-Cyclopentylamino-5-formyl-pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester,  
4-[6-(5-Acetyl-4-cyclopentylamino-pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester,  
2-[5-(4-tert-Butoxycarbonyl-piperazin-1-yl)-pyridin-2-ylamino]-4-cyclopentylamino-pyrimidine-5-carboxylic acid ethyl ester,  
N-Cyclopentyl-N'-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-4,6-diamine,  
N-Isopropyl-N'-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-4,6-diamine,  
4-[6-(6-Cyclopentylamino-pyrimidin-4-ylamino)-pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester,  
N-[5-(3-Amino-pyrrolidin-1-yl)-pyridin-2-yl]-N'-cyclopentyl-pyrimidine-4,6-diamine,  
4-[6-[4-Cyclopentylamino-5-(1-methyl-3-oxo-but-1-enyl)-pyrimidin-2-ylamino]-pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester,  
N-Cyclopentyl-N'-(5-piperazin-1-yl-pyridin-2-yl)-[1,3,5]triazine-2,4-diamine,  
1-[4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidin-5-yl]-ethanone,  
5-Bromo-N4-cyclopentyl-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyridine-2,4-diamine,  
4-Cyclopentylamino-6-(5-piperazin-1-yl-pyridin-2-ylamino)-nicotinonitrile,  
N4-Cyclopentyl-5-nitro-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyridine-2,4-diamine,  
4-Cyclopentylamino-6-(5-piperazin-1-yl-pyridin-2-ylamino)-pyridine-3-carbaldehyde,  
4-Cyclopentylamino-6-(5-piperazin-1-yl-pyridin-2-ylamino)-nicotinic acid ethyl ester,  
4-Cyclopentylamino-6-(5-piperazin-1-yl-pyridin-2-ylamino)-nicotinic acid methyl ester,  
[4-Cyclopentylamino-6-(5-piperazin-1-yl-pyridin-2-ylamino)-pyridin-3-yl]-methanol,

Application No.: 10/759,749  
Confirmation No.: 8348  
Page 7 of 13

1-[4-Cyclopentylamino-6-(5-piperazin-1-yl-pyridin-2-ylamino)-pyridin-3-yl]-ethanone,  
3-[4-Cyclopentylamino-6-(5-piperazin-1-yl-pyridin-2-ylamino)-pyridin-3-yl]-but-2-enoic acid  
ethyl ester,  
(5-Cyclopentyl-5,6-dihydro-pyrido[2,3-e][1,2,4]triazin-3-yl)-(5-piperazin-1-yl-pyridin-2-yl)-  
amine,  
(8-Cyclopentyl-7-methoxy-quinazolin-2-yl)-(5-piperazin-1-yl-pyridin-2-yl)-amine,  
(8-Cyclopentyl-7-methoxy-pyrido[3,2-d]pyrimidin-2-yl)-(5-piperazin-1-yl-pyridin-2-yl)-amine,  
6-Acetyl-8-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pteridin-7-one,  
3-Acetyl-1-cyclopentyl-7-(5-piperazin-1-yl-pyridin-2-ylamino)-1H-pyrido[3,4-b]pyrazin-2-one,  
1-Cyclopentyl-3-ethyl-4-methyl-7-(5-piperazin-1-yl-pyridin-2-ylamino)-3,4-dihydro-1H-  
pyrimido[4,5-d]pyrimidin-2-one,  
1-Cyclopentyl-3-ethyl-4-methyl-7-(5-piperazin-1-yl-pyridin-2-ylamino)-3,4-dihydro-1H-  
pyrido[4,3-d]pyrimidin-2-one,  
3-Acetyl-1-cyclopentyl-4-methyl-7-(5-piperazin-1-yl-pyridin-2-ylamino)-1H-[1,6]naphthyridin-2-  
one,  
(9-Isopropyl-6-methyl-9H-purin-2-yl)-(5-piperazin-1-yl-pyridin-2-yl)-amine,  
2-[9-Isopropyl-6-(5-piperazin-1-yl-pyridin-2-ylamino)-9H-purin-2-ylamino]-ethanol,  
N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(5-piperazin-1-yl-pyridin-2-yl)-9H-purine-2,6-  
diamine,  
2-[9-Isopropyl-6-(5-piperazin-1-yl-pyridin-2-ylamino)-9H-purin-2-ylamino]-3-methyl-butan-1-ol,  
(1-Isopropyl-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-(5-piperazin-1-yl-pyridin-2-yl)-amine,  
2-[1-Isopropyl-4-(5-piperazin-1-yl-pyridin-2-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino]-  
ethanol,  
N6-(4-Amino-cyclohexyl)-1-cyclopentyl-N4-(5-piperazin-1-yl-pyridin-2-yl)-1H-pyrazolo[3,4-  
d]pyrimidine-4,6-diamine,  
2-[1-Isopropyl-4-(5-piperazin-1-yl-pyridin-2-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino]-  
3-methyl-butan-1-ol,  
5-Cyclopentyl-7-(1-hydroxy-ethyl)-8-methyl-3-(5-piperazin-1-yl-pyridin-2-ylamino)-5H-  
pyrido[3,2-c]pyridazin-6-one,  
5-Cyclopentyl-8-methyl-3-(5-piperazin-1-yl-pyridin-2-ylamino)-5H-pyrido[3,2-c]pyridazin-6-  
one,  
7-Benzyl-5-cyclopentyl-3-(5-piperazin-1-yl-pyridin-2-ylamino)-5H-pyrido[3,2-c]pyridazin-6-  
one,  
[5-(1,1-Dioxo-116-thiomorpholin-4-yl)-pyridin-2-yl]-(4-isopropyl-3-methoxy-2-methyl-  
[1,7]naphthyridin-6-yl)-amine,  
(2-Ethyl-4-isopropyl-3-methoxy-[1,7]naphthyridin-6-yl)-pyridin-2-yl-amine,

Application No.: 10/759,749

Confirmation No.: 8348

Page 8 of 13

(2,4-Diisopropyl-3-methoxy-[1,7]naphthyridin-6-yl)-(5-isopropenyl-pyridin-2-yl)-amine,  
[4-(2-Ethylamino-pyridin-4-yl)-pyrimidin-2-yl]-(5-piperazin-1-yl-pyridin-2-yl)-amine,  
[4-(5-Ethyl-2-methylamino-pyridin-4-yl)-pyrimidin-2-yl]-(5-morpholin-4-yl-pyridin-2-yl)-amine,  
[5-Methoxy-4-(2-methylamino-pyridin-4-yl)-pyrimidin-2-yl]-(5-morpholin-4-yl-pyridin-2-yl)-  
amine, and  
5-Fluoro-N4-isopropyl-N2-(5-piperazin-1-yl-pyridin-2-yl)-pyrimidine-2,4-diamine.

12. (original) A method of treating a disorder or condition caused by abnormal cell proliferation in a mammal comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.
13. (original) The method of claim 12 wherein the disorder or condition being treated is selected from the group consisting of vascular smooth muscle proliferation associated with atherosclerosis, postsurgical vascular stenosis and restenosis, and endometriosis.
14. (original) A method of treating a disorder or condition caused by infections selected from the group consisting of viral infections such as DNA viruses like herpes and RNA viruses like HIV, and fungal infections in a mammal comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.
15. (original) A method of treating disorders selected from the group consisting of autoimmune diseases selected from the group consisting of psoriasis, inflammation like rheumatoid arthritis, lupus, type 1 diabetes, diabetic nephropathy, multiple sclerosis, glomerulonephritis, organ transplant rejection, including host versus graft disease in a mammal comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.
16. (original) The method of treating neurodegenerative disorders in a mammal comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.
17. (original) The method of claim 12 wherein the abnormal cell proliferation is a cancer selected from the group consisting of cancers of the breast, ovary, cervix, prostate, testis, esophagus, stomach, skin, lung, bone, colon, pancreas, thyroid, biliary passages, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, glioblastoma, neuroblastoma, keratoacanthoma,

Application No.: 10/759,749

Confirmation No.: 8348

Page 9 of 13



epidermoid carcinoma, large cell carcinoma, adenocarcinoma, adenocarcinoma, adenoma,  
adenocarcinoma, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma,  
seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma, kidney carcinoma,  
myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, and leukemia.

Application No.: 10/759,749  
Confirmation No.: 8348  
Page 10 of 13